National
U.S. commission considers ways to stop anti-gay Uganda bill
U.S. Rep. Tammy Baldwin (D-Wis.) (DC Agenda photo by Michael Key)
Greater involvement from first lady Michelle Obama was one option discussed during a recent congressional hearing as a way for the U.S. to help derail a harshly anti-gay bill in Uganda from becoming law.
Cary Alan Johnson, executive director of the International Gay & Lesbian Human Rights Commission, was among the people who testified before the Tom Lantos Human Rights Commission on Thursday that Obama’s work against the international HIV/AIDS epidemic would make her a strong voice against the bill.
Johnson said the women’s caucus in the Ugandan parliament is supporting the legislation and opposition from the first lady — as well as President Obama — could influence women’s groups in Uganda to drop their support.
“I’m wondering if there is women leaders within the U.S. Congress — and perhaps the first lady herself — might be able to play some role in having discussions about the potential impact of this bill — not just on human rights, but on HIV prevention within the country,” Johnson said.
Julius Kaggwa, a leader of the Civil Society Coalition on Human Rights & Constitutional Law who came from Uganda to testify on the legislation, also said greater involvement from President Obama and Michelle Obama would be helpful in efforts to stop the bill.
“If President Obama and the first lady of the United States can engage more with our first family — especially in the area of HIV/AIDS, which is of great concern to us as sexual minorities — and the issue of human rights generally, I think that would be very, very helpful,” he said.
A stronger voice from the first lady and President Obama was one among several options considered to stop the anti-gay legislation that’s been pending the Uganda parliament since October.
Homosexual acts are already illegal in Uganda, but the bill would, among other things, institute the death penalty for repeat offenders of the homosexual acts ban and for those who have homosexual sex while HIV positive. The harsh penalties for LGBT people in the legislation have inspired growing outrage and concern around the world, including LGBT activists in the U.S.
Karl Wycoff, deputy assistant secretary of state for East African Affairs (DC Agenda photo by Michael Key)
Karl Wycoff, deputy assistant secretary of state for East African Affairs, testified that the State Department has been working to prevent the bill from being enacted into law even as the U.S. considers the country an ally.
“The introduction of this anti-homosexuality bill in Uganda characterizes just such a moment — one where we must say to our friends who’s friendship we value that together we must stand against injustice, and in this case, injustice against the LGBT community,” he said.
Wycoff noted how the White House in January issued a statement in opposition to the legislation and said Secretary of State Hillary Clinton has expressed concerns about the bill with Ugandan President Yoweri Museveni in addition to publicly opposing the legislation in two speeches.
“Our embassy … has been very active on this subject with representatives of the Ugandan government, with civil society, with local gay and lesbian groups and with others who press for this bill to be dropped,” Wycoff said.
Last month, DC Agenda first reported State Department officials had received assurances from Museveni that he would work to block the legislation from becoming law and would veto the bill should it come to his desk. But during the hearing, Wycoff declined to characterize publicly the discussions the State Department had with the president.
Witnesses also discussed efforts of activists within Uganda working to prevent the bill from becoming law. Kaggwa said local groups have been trying to stop the measure, but noted that persuading lawmakers to oppose the bill is difficult because of the country’s deep cultural beliefs against homosexuality.
Kaggwa said one of the best points for opponents to bring up about the legislation is how it would require Ugandan citizens to report on those believed to be homosexual.
“The element of setting a mother against a daughter, the element of setting a sister against a brother, is something that we all can identify with,” Kaggwa said. “These are the arguments that we are using. We should make this bill really draconian, that instead of bringing together families, instead of preserving family, as purported by people who are pushing the bill, it’s [separating] families.”
Following the testimony, lesbian Rep. Tammy Baldwin (D-Wis.), who chaired the hearing, told reporters that bolstering the local effort in Uganda against the legislation would be one means for the United States to step up efforts against the bill.
“I do think it is important for us to listen and receive guidance from people on the ground in Uganda — not just thinking from afar what to do,” she said. “I think there’s probably additional ways where we can empower local activists, local voices in Uganda at the same time as we speak crystal clear our dedication to human rights for all [people] across the globe.”
Another option lawmakers are considering is revoking Uganda’s beneficiary trade status should the bill become law. Baldwin noted during the hearing that earlier this month, Sen. Ron Wyden (D-Ore.) sent a letter to Clinton saying Uganda’s trade relationship with the United States would be revoked if the country’s parliament enacts the legislation.
While a number of strategies were put forth as ways to prevent the legislation from becoming law, one option witnesses denied as being an appropriate response was restriction of funds under the President’s Emergency Plan for AIDS Relief. The program, also known as PEPFAR, is a multi-billion dollar initiative started by former President George W. Bush that provides treatment for people living with HIV/AIDS in developing countries.
Christine Lubinski, executive director of the HIV Medicine Association, said the $1.3 billion that the U.S. spends in aid to Uganda is “too much of a day-to-day lifeline for too many people.”
“It seems like there’s significant other avenues to pursue; the HIV money would not be good one,” she said.
But Johnson said there could be other avenues to pursue with AIDS relief money if Uganda passes the legislation. He said PEPFAR money could be “channeled differently” to non-governmental organizations that would implement HIV/AIDS relief programs in the country.
Another concern raised during the hearing was whether international efforts would have an adverse effect on stopping the anti-gay legislation because of the country’s history under colonial rule.
Wycoff said attention from the international community has actually contributed to some efforts in Uganda calling for the passage of the legislation.
“Ironically, foreign criticism of the bill has in some ways bolstered internal support for the legislation as many Ugandans interpret foreign condemnation as interference in their internal affairs,” he said.
But Kaggwa said international concern about the legislation is helpful, so long as local opposition against the bill is heard just as strongly.
Julius Kaggwa, a leader of the Civil Society Coalition on Human Rights & Constitutional Law (DC Agenda photo by Michael Key)
“It is important that these local, indigenous voices are heard as heavily or as loudly as the international voices,” he said. “We believe that if that voice supplements our own voices, then we will be productive. But if the foreign voices are louder than ours, then I’m afraid that might have a counter-productive effect.”
Johnson said people opposed to the legislation are working to make sure both local and regional voices are heard against the bill, and that Obama could make the local voices stronger.
“I think that could be an aspect in which the administration could be more proactive in terms of talking to other African nations, and talking to the African Union, about making its voice heard on the legislation,” he said.
A number of Democratic U.S. House members spoke out against the bill during the hearing. Rep. Jim McGovern (D-Mass.), co-chairman of the commission, said the bill “is steeped in religious bigotry and homophobia.”
“I want to make it clear that there are many members in this Congress — both Democrat and Republican — who have deep, deep concerns about what’s happening in Uganda and are outraged by this draft legislation,” he said.
Baldwin called the legislation “an extreme and hateful attempt to make people criminals not because of anything they do, but because of who they are and who they love.”
She noted that 90 other U.S. House members joined her in signing a letter to presidents Obama and Museveni, requesting their strong opposition to the legislation.
“I hope that all Ugandans, and particularly those who are [LGBT], will hear the voice of this Congress state very clearly that we will not tolerate these types of human rights violations,” she said.
No Republican member of the commission attended the hearing. A Republican staffer for the commission didn’t immediately respond to DC Agenda’s request to comment on why GOP members were absent.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Kazakh president signs anti-LGBTQ propaganda bill
Top 10 LGBTQ local news stories of 2025
The 25 greatest queer movies of the 21st century so far
How to cope when a partner gives you the silent treatment
Out actor talks lead role in ‘Fiddler on the Roof’
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
